Agent Orange Exposure, Cytogenetics, and Clinical Outcomes in Multiple Myeloma and MGUS Patients

被引:0
作者
Kulkami, P. [1 ,2 ]
Hall, J. A. [1 ,2 ]
Copeland, L. A. [3 ,4 ]
Nangrani, A. [1 ]
Dodlapati, J. [1 ,2 ]
机构
[1] Cent Texas Vet Hlth Care Syst, Temple, TX USA
[2] Baylor Scott & White Hlth, Dallas, TX USA
[3] VA Cent Western Massachusetts Healthcare Syst, Northampton, MA 01062 USA
[4] Univ Massachusetts, Chan Med Sch, Worcester, MA 01106 USA
来源
JOURNAL OF MILITARY AND VETERANS HEALTH | 2024年 / 32卷 / 02期
关键词
MONOCLONAL GAMMOPATHY; POOR-PROGNOSIS; LONG-TERM; CHROMOSOME-13; DELETION;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background While considerable research has examined transformation from monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM) and the association of Agent Orange (AO) with MM, adverse cytogenetics are understudied. Purpose To evaluate associations between AO and adverse cytogenetics or other poor prognostic factors such as abnormal light chain ratio in aged veterans with MM. Materials and methods Vietnam -era Veterans diagnosed with MM or MGUS at a Veterans Health Administration site were identified. Chart review abstracted presence of 17p13, t(4;14), t(14;16), t(14;20), and Gain lq by FISH (dubbed FISH-5) and q13/13q14 deletion, kappa/lambda ratio <.03 / >32 for MM (<.256 / >1.65 for MGUS), and bone marrow plasma cell percentage for MM. Results Among 238 veterans, 70 had MM and 192 MGUS; 24 had both diagnoses (transformation). In MGUS, AO was not associated with transformation, although kappa/lambda ratio was. In MM, Hispanic veterans had more AO exposure. Survival was unassociated with AO or adverse cytogenetics, while Hispanic veterans experienced increased mortality. Conclusion Our study explored cytogenetics in MM among surviving Vietnam Veterans with and without AO exposure. Although Hispanic veterans were more likely to have AO exposure, Hispanic ethnicity but not AO was associated with poorer survival.
引用
收藏
页码:27 / 33
页数:7
相关论文
共 43 条
  • [31] Outcomes of patients with multiple myeloma harboring chromosome 1q gain/amplification in the era of modern therapy
    Hu, Xiao
    Wu, Cherng-Horng
    Cowan, Janet M.
    Comenzo, Raymond L.
    Varga, Cindy
    ANNALS OF HEMATOLOGY, 2022, 101 (02) : 369 - 378
  • [32] Phase II trial of single-agent panobinostat consolidation improves responses after sub-optimal transplant outcomes in multiple myeloma
    Mithraprabhu, Sridurga
    Kalff, Anna
    Gartlan, Kate H.
    Savvidou, Ioanna
    Khong, Tiffany
    Ramachandran, Malarmathy
    Cooke, Rachel E.
    Bowen, Kathryn
    Hill, Geoffrey R.
    Reynolds, John
    Spencer, Andrew
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 (01) : 160 - 170
  • [33] Clinical significance of chromosomal abnormalities detected by interphase fluorescence in situ hybridization in newly diagnosed multiple myeloma patients
    Hu Yu
    Chen Lei
    Sun Chun-yan
    She Xiao-mei
    Ai Li-sha
    Qin You
    CHINESE MEDICAL JOURNAL, 2011, 124 (19) : 2981 - 2985
  • [34] Clinical Features and Treatment Response of Light Chain (AL) Amyloidosis Diagnosed in Patients With Previous Diagnosis of Multiple Myeloma
    Madan, Sumit
    Dispenzieri, Angela
    Lacy, Martha Q.
    Buadi, Francis
    Hayman, Suzanne R.
    Zeldenrust, Steven R.
    Rajkumar, S. Vincent
    Gertz, Morie A.
    Kumar, Shaji K.
    MAYO CLINIC PROCEEDINGS, 2010, 85 (03) : 232 - 238
  • [35] Yearly Assessment of Bone Disease in Patients with Asymptomatic Multiple Myeloma Identifies Early Progression Events and Should Be the Standard Clinical Practice
    Ntanasis-Stathopoulos, Ioannis
    Koutoulidis, Vassilis
    Malandrakis, Panagiotis
    Fotiou, Despina
    Spiliopoulou, Vasiliki
    Filippatos, Charalampos
    Migkou, Magdalini
    Kanellias, Nikolaos
    Theodorakakou, Foteini
    Eleutherakis-Papaiakovou, Evangelos
    Kastritis, Efstathios
    Terpos, Evangelos
    Dimopoulos, Meletios-Athanasios
    Moulopoulos, Lia-Angela
    Gavriatopoulou, Maria
    JOURNAL OF CLINICAL MEDICINE, 2025, 14 (07)
  • [36] Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients
    Paiva, B.
    Gutierrez, N-C
    Chen, X.
    Vidriales, M-B
    Montalban, M-A
    Rosinol, L.
    Oriol, A.
    Martinez-Lopez, J.
    Mateos, M-V
    Lopez-Corral, L.
    Diaz-Rodriguez, E.
    Perez, J-J
    Fernandez-Redondo, E.
    de Arriba, F.
    Palomera, L.
    Bengoechea, E.
    Terol, M-J
    de Paz, R.
    Martin, A.
    Hernandez, J.
    Orfao, A.
    Lahuerta, J-J
    Blade, J.
    Pandiella, A.
    San Miguel, J-F
    LEUKEMIA, 2012, 26 (08) : 1862 - 1869
  • [37] Venous thromboembolism prophylaxis and multiple myeloma patients in real-life: Results of a large survey and clinical guidance recommendations from the IFM group
    Frenzel, Laurent
    Decaux, Olivier
    Macro, Margaret
    Belhadj-Merzoug, Karim
    Manier, Salomon
    Touzeau, Cyrille
    Leleu, Xavier
    Frere, Corinne
    Lecompte, Thomas
    Perrot, Aurore
    Avet-Loiseau, Herve
    Moreau, Philippe
    Chalayer, Emilie
    THROMBOSIS RESEARCH, 2024, 233 : 153 - 164
  • [38] Clinical characteristics and prognostic value of 1q21 gain detected by fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma
    Xiao Xiao
    Fang, Xinchen
    Wen Yao
    Zhu Huaiping
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2022, 15 (01) : 90 - 93
  • [39] Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience
    Pasvolsky, Oren
    Ghanem, Sassine
    Milton, Denai R.
    Rauf, Mikael
    Tanner, Mark R.
    Bashir, Qaiser
    Srour, Samer
    Saini, Neeraj
    Lin, Paul
    Ramdial, Jeremy
    Nieto, Yago
    Tang, Guilin
    Aljawai, Yosra
    Khan, Hina N.
    Kebriaei, Partow
    Lee, Hans C.
    Patel, Krina K.
    Thomas, Sheeba K.
    Weber, Donna M.
    Orlowski, Robert Z.
    Shpall, Elizabeth J.
    Champlin, Richard E.
    Qazilbash, Muzaffar H.
    BLOOD CANCER JOURNAL, 2024, 14 (01)
  • [40] Real-World Outcomes in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma Treated With Bortezomib/Cyclophosphamide/Dexamethasone and Bortezomib/Lenalidomide/Dexamethasone as Upfront Treatment
    Saeed, Nabiha
    Khan, Zurrya
    Jehanzeb, Hamzah
    Shaikh, Taha
    Shaikh, Usman
    Adil, Salman N.
    Madni, Varisha
    Fatima, Hania
    Abiha, Umm E.
    Ali, Natasha
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (04)